Melanie Hiester
Family · Newark, DENPI 1689006256
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 648 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 648 payments — averaging $13.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch Health US, LLC$2K
- AbbVie$807
- Takeda Pharmaceuticals U.S.A., Inc.$593
- Alkermes, Inc.$591
- Axsome Therapeutics, Inc.$573
- Otsuka America Pharmaceutical, Inc.$554
- plus $4K from 30 others
What the payments were for
- Food & beverage$8,998100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch Health US, LLC | 211 | $1,735 |
| AbbVie | 60 | $807 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $593 |
| Alkermes, Inc. | 32 | $591 |
| Axsome Therapeutics, Inc. | 32 | $573 |
| Otsuka America Pharmaceutical, Inc. | 36 | $554 |
| Tris Pharma Inc | 35 | $455 |
| Corium, LLC | 22 | $407 |
| Collegium Pharmaceutical, Inc. | 20 | $373 |
| Ironshore Pharmaceuticals Inc. | 24 | $361 |
| Lundbeck LLC | 18 | $317 |
| Novo Nordisk | 17 | $307 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $242 |
| Sunovion Pharmaceuticals Inc. | 14 | $229 |
| Supernus Pharmaceuticals, Inc. | 9 | $161 |
| Lilly USA, LLC | 8 | $151 |
| E.r. Squibb & Sons, L.L.C. | 6 | $133 |
| Exact Sciences | 8 | $126 |
| Vanda Pharmaceuticals Inc. | 7 | $123 |
| Johnson & Johnson | 6 | $106 |
| Teva Pharmaceuticals USA, Inc. | 5 | $101 |
| Neurocrine Biosciences, Inc. | 5 | $79 |
| Sage Therapeutics, LLC | 3 | $56 |
| Biohaven Pharmaceuticals, Inc. | 3 | $55 |
| Idorsia Pharmaceuticals US Inc | 3 | $53 |
| Adlon Therapeutics L.p. | 3 | $51 |
| Pfizer | 3 | $49 |
| Eisai Inc. | 3 | $42 |
| Avanir Pharmaceuticals, Inc. | 2 | $34 |
| Biogen | 1 | $24 |
| Neos Therapeutics, LP | 1 | $21 |
| GSK | 1 | $20 |
| Noven Therapeutics, LLC | 1 | $19 |
| AstraZeneca | 1 | $19 |
| Astellas Pharma US Inc | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JORNAY PM$125
How this compares
$9,000 in reported general payments places this provider in the 95th percentile of 523 family providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 39 | $81,237 |
| Lurasidone Hcl | 15 | $6,607 |
| Lisdexamfetamine Dimesylate | 11 | $4,712 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 52 | $3,132 |
| Duloxetine Hcl | 83 | $2,540 |
| Eszopiclone | 13 | $1,362 |
| Mirtazapine | 51 | $1,261 |
| Trazodone Hcl | 34 | $975 |
| Quetiapine Fumarate | 74 | $822 |
| Bupropion XlBupropion Hcl | 52 | $805 |
| Prazosin Hcl | 25 | $792 |
| Alprazolam | 46 | $736 |
| Escitalopram Oxalate | 39 | $719 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 21 | $604 |
| Gabapentin | 26 | $530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $807 | $81,23739 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 523 family providers in Delaware.
Other family in Newark
- Kathy GallagherNewark$53K
- Jodie DelesioNewark$50K
- Samatha GrayNewark$9K
- Byron MayNewark$8K
- Clare MatisNewark$8K
- Christine MazzolaNewark$7K
- Kelsey FrybergerNewark$7K
- Colleen AllenNewark$7K
- Mallory KowalskiNewark$7K
- Palak DesaiNewark$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.